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Abstract
Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a lethal and sometimes familial ovarian tumour
of young women and children. We and others recently discovered that over 90% of SCCOHTs harbour inactivating
mutations in the chromatin remodelling gene SMARCA4 with concomitant loss of its encoded protein SMARCA4
(BRG1), one of two mutually exclusive ATPases of the SWI/SNF chromatin remodelling complex. To determine the
specificity of SMARCA4 loss for SCCOHT, we examined the expression of SMARCA4 by immunohistochemistry
in more than 3000 primary gynaecological tumours. Among ovarian tumours, it was only absent in clear cell
carcinoma (15 of 360, 4%). In the uterus, it was absent in endometrial stromal sarcomas (4 of 52, 8%) and
high-grade endometrioid carcinomas (2 of 338, 1%). Recent studies have shown that SMARCA2 (BRM), the other
mutually exclusive ATPase of the SWI/SNF complex, is necessary for survival of tumour cells lacking SMARCA4.
Therefore, we examined SMARCA2 expression and discovered that all SMARCA4-negative SCCOHTs also lacked
SMARCA2 protein by IHC, including the SCCOHT cell lines BIN67 and SCCOHT1. Among ovarian tumours, the
SMARCA4/SMARCA2 dual loss phenotype appears completely specific for SCCOHT. SMARCA2 loss was not due
to mutation but rather from an absence of mRNA expression, which was restored by treatment with the histone
deacetylase inhibitor trichostatin A. Re-expression of SMARCA4 or SMARCA2 inhibited the growth of BIN67 and
SCCOHT1 cell lines. Our results indicate that SMARCA4 loss, either alone or with SMARCA2, is highly sensitive and
specific for SCCOHT and that restoration of either SWI/SNF ATPase can inhibit the growth of SCCOHT cell lines.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Background – SCCOHT
Small cell carcinoma of the ovary, hypercalcaemic type
(SCCOHT) is a rare ovarian cancer that predominantly
affects young women in their teens and 20s, with an
average age of 24 years. Although half of tumours are
diagnosed at an early stage, the prognosis is dismal. For
patients with stage IA disease, more than half will still
die of disease, usually within 2 years [1]. Histologically,
SCCOHT is characterized by sheets and poorly formed
nests of small cells with scant cytoplasm, hyperchro-
matic nuclei, and small nucleoli [1]. Approximately half
of tumours also contain variable numbers of large cells
with abundant eosinophilic cytoplasm, often rhabdoid
inclusions, large nuclei, and prominent nucleoli. The
histological differential diagnosis is broad and includes
many primary and metastatic tumours to the ovary. The
lack of familiarity of pathologists with this rare tumour
and the lack of specific immunohistochemical markers
can make its diagnosis challenging.
SMARCA4 in SCCOHT and cancer
Recently, four groups independently identified inacti-
vating SMARCA4 mutations in the majority of SCCO-
HTs, resulting in loss of SMARCA4 protein [2–5].
SMARCA4 and the related protein SMARCA2 (also
called BRG1 and BRM, respectively) are the two mutu-
ally exclusive ATPases of the SWI/SNF chromatin
remodelling complex [6–8]. SWI/SNF subunits have
been frequently implicated as tumour suppressors, with
approximately 20% of cancers bearing mutations in
these genes [9,10]. Our initial analysis of a small collec-
tion of ovarian tumours indicated that SMARCA4 loss
was highly specific for SCCOHT [2].
Potential therapeutic strategies for SCCOHT
The function of the SWI/SNF complex in chromatin
remodelling suggests that the pathogenesis of SCCOHT
involves epigenetic dysregulation. This paradigm may
offer treatment possibilities with agents that regulate
the epigenome such as inhibitors of histone deacety-
lase (HDAC) or modifiers of histone or DNA methyla-
tion. The mutually exclusive nature of the SMARCA4
and SMARCA2 ATPases in the SWI/SNF complex has
suggested that SMARCA2 may be a synthetic lethal
target in SMARCA4-mutant cancers. Indeed, loss of
SMARCA4 has been shown to lead to dependence on
SMARCA2-containing SWI/SNF complexes for sur-
vival in some cell lines [11–13], raising the possibility
of targeting SMARCA2 in SCCOHT using inhibitors of
its ATPase or bromodomain.
Aims of this study
The establishment of SMARCA4 mutation with accom-
panying loss of protein as the pathognomonic mutation
in SCCOHT raises the need to explore the spectrum
of tumours that share SMARCA4 (and perhaps
SMARCA2) loss to understand the diagnostic utility
of SMARCA4 immunohistochemistry (IHC). Because
some ovarian and uterine tumours arise from common
cell types (eg endometrial epithelium, either in the
eutopic endometrium or ectopically as endometriosis),
we also need to determine the diagnostic utility of
SMARCA4 IHC in uterine tumours. Therefore, the
goals of this study were (1) to determine the specificity
of SMARCA4 protein loss as a diagnostic marker for
SCCOHT by studying its expression in a large cohort
of ovarian and uterine tumours with an emphasis on
entities in the differential diagnosis; and (2) to deter-
mine whether SMARCA2 is expressed in SCCOHT and
could be used as a therapeutic target.
Materials and methods
Sample collection and tissue microarray
construction
Duplicate 0.6 or 1.0mm cores of formalin-fixed,
paraffin-embedded tumour tissue from each case were
used for tissue microarray (TMA) construction, as
described previously [14]. Additional cases were stud-
ied by whole-slide IHC. All samples were collected in
accordance with institutional guidelines and protocols.
For Vancouver samples, informed patient consent was
obtained under research ethics board (REB)-approved
protocols for all prospectively collected patient samples
(REB H05-60 199), archived samples (REB H02-61
375), and for IHC analysis (REB H02-61375).
Immunohistochemistry and scoring
TMAs were cut at 4 μm thickness onto Superfrost+
glass slides and were processed using the Ventana
Discovery XT, and the Ventana Benchmark XT and
Benchmark Ultra automated systems (Ventana Medi-
cal Systems, Tucson, AZ, USA). Immunohistochemical
staining was performed with antibodies to SMARCA4
(1:25, clone EPNCIR111A, ab110641; Abcam, Toronto,
Ontario, Canada), SMARCA2 (1:50, clone HPA029981;
Sigma, St Louis, MO, USA), and SMARCB1/BAF47/
INI1 (1:50, 25/BAF47, 612110; BD Biosciences, Mis-
sissauga, Ontario, Canada).
All TMAs were scored twice by a pathologist (ANK).
For SMARCA4, tumours were scored as positive if
any tumour cell nuclei showed staining; tumours scored
as positive usually showed diffuse, moderate to strong
staining. Tumours were scored as negative if tumour
cell nuclei showed no staining only if adequate staining
was detected in internal positive control cells (endothe-
lium, lymphocytes or fibroblasts); absence of staining
has previously been shown to correlate with the presence
of inactivating mutations in SMARCA4 [2–5,15]. No
cytoplasmic SMARCA4 staining was observed. Since
SMARCA2 absence was due to non-mutational silenc-
ing, tumours were scored as positive for SMARCA2 if
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more than 5% of tumour cells showed nuclear staining.
Tumours were scored as negative if tumour cells showed
no nuclear staining, nuclear staining in up to 5% of cells,
or only cytoplasmic staining. For both SMARCA4 and
SMARCA2, tumours that showed no staining in tumour
and stroma were considered technical failures and not
scored. Each case on a TMA was represented as dupli-
cate cores; one positive core was sufficient to count the
case as positive.
Cell lines
BIN67, SCCOHT1, and KGN cells were all grown in
DMEM/F-12 supplemented with 10% FBS. SVOG3e
cells were cultured in 199/105 medium with 10% FBS.
ES-2 cells were cultured in RPMI supplemented with
10% FBS. All the cells were maintained in a humidi-
fied 5% CO2-containing atmosphere at 37
∘C and tested
regularly for Mycoplasma.
Plasmids and lentivirus/retrovirus packaging
The pLDpuro-SMARCA4 and pLDpuro-SMARCA2
plasmids were constructed by introducing the
SMARCA4 and SMARCA2 from entry vectors
(Genecopeia) into the pLDpuro-EnVA destination
vector (a gift of Dr Jason Moffat at the University
of Toronto) using Gateway reactions (Life Tech-
nologies, Grand Island, NY, USA). To produce
lentiviruses expressing SMARCA4 or SMARCA2,
pLDpuro-SMARCA4 or pLDpuro-SMARCA2 was
co-transfected with packaging plasmids psPAX2 and
pMD2.G into HEK293T cells. Supernatants were
collected at 72 h for lentivirus preparation and infection.
Western blotting
Whole-cell extracts were obtained for SDS-PAGE elec-
trophoresis using the SMARCA4 and SMARCA2 anti-
bodies described above. Ponceau S staining or western
blotting for vinculin (clone hVIN-1, V9131; Sigma) was
used to confirm equal protein loading.
Real-time RT-PCR
Total RNA was extracted from cells using RNeasy
kits (Qiagen, Valencia, CA, USA) and quantitated by
Nanodrop spectrophotometry. One microgram of total
RNA was reverse-transcribed into cDNA using ran-
dom primers and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA), followed by PCR
amplification of SMARCA4 or SMARCA2 using the
Power SYBR® Green Master Mix (Life Technologies)
according to the manufacturers’ instructions. GAPDH
was used for normalization. The relative levels were
calculated using the ΔΔCt method.
RNA isolation and gene expression microarrays
Frozen tumour tissue was disrupted by sonication using
the Covaris S-2 system (Thermo Fisher Scientific,
Waltham, MA, USA) and stabilized by addition of
equal volumes of TRIzol (Life Technologies). BIN67
and SCCOHT1 cells were washed with PBS and lysed
using TRIzol. Total RNA was purified using RNeasy
micro kits (Qiagen). RNA from two premenopausal nor-
mal ovary donors (ages 32 and 37 years) was obtained
from OriGene (Rockville, MD, USA), pooled (100 ng
each), and used as a common reference. RNA integrity
and purity were measured using a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) and
a Nanodrop ND-1000 Spectrophotometer. Labelled
cRNA probes were prepared using Agilent’s Low Input
Quick Amp Labeling Kit and hybridized to Agilent
Human Gene Expression 4× 44K microarrays follow-
ing the manufacturer’s protocols. Slides were washed
and scanned at 5 μm using an Agilent Microarray
Scanner (model G2505B) in an ozone-controlled envi-
ronment, and data extracted, processed, and normalized
using Agilent Feature Extraction (FE) software (v10.5).
Raw and processed data files have been deposited in
GEO at accessions GSE49887 and GSE66434.
Cell growth assay
Cells were infected with lentivirus containing pLDpuro-
GFP, −SMARCA4 or -SMARCA2. One day later, cells
were selected in 2 μg/ml puromycin for 3 days. The
remaining cells were then harvested, counted, and
reseeded at a density of 4000 cells per well in 96-well
plates. Cell growth was monitored using the IncuCyte
ZOOM® live cell imaging monitor (Essen BioScience,
Ann Arbor, MI, USA). The percentage of confluence in
each well was calculated and plotted over a 7-day period
to determine the effect of SMARCA4 or SMARCA2
re-expression on cell growth.
Results
SMARCA4 expression in gynaecological
and non-gynaecological tumours
We previously studied SMARCA4 protein status in
a small series of 485 primary ovarian tumours where
besides SCCOHT, only two tumours (0.4%), both clear
cell carcinomas, were negative for SMARCA4 [2]. In
order to perform a definitive analysis of the sensitiv-
ity and specificity of SMARCA4 loss for SCCOHT
and thus, its potential as a diagnostic immunohis-
tochemical marker, we expanded SMARCA4 IHC
analysis to additional cases of SCCOHT and a
large series of 3048 primary ovarian and uterine
tumours and non-gynaecological mimics of SCCOHT
(Table 1).
Examination of SMARCA4 expression in 50
SCCOHT-derived samples (20 reported previously
[2,15] and 30 new cases reported here) revealed
SMARCA4 loss in 42/46 (91%) primary tumours, 2/2
patient-derived mouse xenografts, and 2/2 SCCOHT-
derived cell lines (Table 1). Of the four tumours
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Table 1. SMARCA4 immunohistochemical analysis in ovarian,





Primary tumours 46 42 (91%)
Patient-derived xenografts 2 2 (100%)
Cell lines 2 2 (100%)
Subtotal 50 46 (92%)
Ovarian epithelial tumours
High-grade serous carcinoma 1198 0 (0%)
Clear cell carcinoma 360 15 (4%)
Endometrioid adenocarcinoma 258 0 (0%)
Endometrioid adenocarcinoma, mixed 9 0 (0%)
Endometrioid borderline tumour 1 0 (0%)
Low-grade serous carcinoma 53 0 (0%)
Serous borderline tumour 23 0 (0%)
Mucinous carcinoma 98 0 (0%)
Mucinous borderline tumour 6 0 (0%)
Mixed mucinous tumour 5 0 (0%)
Anaplastic carcinoma in mucinous carcinoma 1 0 (0%)
Mixed carcinoma 1 0 (0%)
Undifferentiated carcinoma 18 0 (0%)
Carcinosarcoma 27 0 (0%)
Benign Brenner tumour 3 0 (0%)
Borderline Brenner tumour 1 0 (0%)
Malignant Brenner tumour 2 0 (0%)
Small cell carcinoma, pulmonary type 3 0 (0%)
Ovarian carcinoma, not otherwise specified 5 0 (0%)
Subtotal 2072 15 (1%)
Ovarian/adnexal sex cord-stromal tumours
Adult granulosa cell tumour 113 0 (0%)
Juvenile granulosa cell tumour 29 0 (0%)
Fibroma/fibrosarcoma 8 0 (0%)
Thecoma 7 0 (0%)
Sertoli–Leydig cell tumour 41 0 (0%)
Leydig cell tumour 2 0 (0%)
Sclerosing stromal tumour 6 0 (0%)
Sex cord tumour with annular tubules 2 0 (0%)
Steroid cell tumour 1 0 (0%)
Sex cord tumour, not otherwise specified 4 0 (0%)
Female adnexal tumour of Wolffian origin 4 0 (0%)
Gynandroblastoma 3 0 (0%)
Endometrioid stromal sarcoma 1 0 (0%)
Subtotal 221 0 (0%)
Ovarian germ cell tumours
Dysgerminoma 5 0 (0%)
Yolk sac tumour 6 0 (0%)
Dysgerminoma and yolk sac tumour 1 0 (0%)
Mature teratoma 3 0 (0%)
Immature teratoma 6 0 (0%)
Carcinoid tumour 4 0 (0%)
Strumal carcinoid in a mucinous cystadenoma 2 0 (0%)
Sebaceous carcinoma in a dermoid cyst 1 0 (0%)
Squamous cell carcinoma 3 0 (0%)
Subtotal 31 0 (0%)
Uterine epithelial tumours
Endometrioid adenocarcinoma 336 1 (0%)
Clear cell carcinoma 28 0 (0%)
High-grade serous carcinoma 94 0 (0%)
Mucinous carcinoma 3 0 (0%)
Mixed carcinoma 11 0 (0%)
Large cell carcinoma 1 0 (0%)
Small cell carcinoma 3 0 (0%)
Undifferentiated carcinoma 3 0 (0%)
Dedifferentiated carcinoma 2 1 (50%)





Subtotal 546 2 (0%)
Uterine mesenchymal tumours
Leiomyoma 49 0 (0%)
Leiomyosarcoma 21 0 (0%)
Endometrial stromal sarcoma 52 4 (8%)
Undifferentiated endometrial sarcoma 1 0 (0%)
Rhabdomyosarcoma 2 0 (0%)
Adenosarcoma 7 0 (0%)
Uterine tumour resembling ovarian sex cord
tumour
2 0 (0%)
Subtotal 134 4 (3%)
Non-gynaecological tumours
Alveolar rhabdomyosarcoma 10 0 (0%)
Embryonal rhabdomyosarcoma 10 0 (0%)
Desmoplastic small round cell tumour 2 0 (0%)
Ewing’s sarcoma 9 0 (0%)
Synovial sarcoma, monophasic 3 0 (0%)
Synovial sarcoma, biphasic 2 0 (0%)
Melanoma 7 0 (0%)
Follicular lymphoma 1 0 (0%)
Subtotal 44 0 (0%)
Total 3048 21 (1%)
that retained SMARCA4 expression, three lacked
SMARCB1 (also called BAF47 or INI1), a differ-
ent core member of the SWI/SNF complex. One
of the three SMARCB1-negative tumours showed
biallelic inactivation of SMARCB1. In the remaining
SMARCA4-positive case, exome sequencing revealed
no mutations in SWI/SNF genes.
We examined SMARC4 expression in 3048 primary
ovarian and uterine tumours and non-gynaecological
mimics of SCCOHT. Among 2324 primary ovarian
epithelial, sex cord-stromal, and germ cell tumours
(including the previously reported 485 tumours [2]),
SMARCA4 loss was only observed in clear cell car-
cinoma (15/360, 4%) (Table 1), a tumour that is not
in the histological differential diagnosis of SCCOHT.
All ovarian tumours in the histological differential diag-
nosis of SCCOHT (including small cell carcinoma
of pulmonary type, adult and juvenile granulosa cell
tumours, Sertoli–Leydig cell tumours, endometrial stro-
mal sarcoma, and dysgerminoma) retained SMARCA4
expression.
Among 680 primary uterine tumours, SMARCA4
loss was observed in endometrioid carcinoma (2/338,
1%) and endometrial stromal sarcoma (ESS, 4/52, 4%;
Table 1). Both endometrioid carcinomas were FIGO
grade 3; one was a dedifferentiated carcinoma [16], a
tumour composed of low-grade endometrioid carcinoma
(FIGO grade 1 or 2) and undifferentiated carcinoma.
Among the ESS cases, two were low-grade and two
were high-grade. One high-grade ESS showed rhab-
doid features. For the SMARCA4-negative dedifferen-
tiated carcinoma and the high-grade ESS cases, only the
high-grade/undifferentiated portions were represented
on the TMAs.
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We also examined SMARCA4 expression in 44
extra-ovarian, non-gynaecological tumours that resem-
ble SCCOHT histologically and can present with
intra-abdominal or ovarian disease mimicking ovarian
carcinoma clinically, including alveolar and embryonal
rhabdomyosarcoma, desmoplastic small round cell
tumour, Ewing’s sarcoma, synovial sarcoma, follicu-
lar lymphoma, and melanoma. All of these tumours
retained SMARCA4 expression (Table 1).
In summary, 46/50 (92%) of all SCCOHT-derived
samples in our series lacked SMARCA4, and 49/50
(98%) lacked a core member of the SWI/SNF complex
(either SMARCA4 or SMARCB1). When combined
with other published SCCOHT cases [3–5], SMARCA4
loss has now been observed in 83/91 cases (91%
sensitivity). Among primary ovarian tumours and
non-gynaecological tumours that can mimic SCCOHT,
we observed SMARCA4 loss in only 15/2368 tumours
(15/2324 ovarian and 0/44 non-gynaecological) for a
specificity of 99% among the tumours examined, and
the only ovarian tumour that lacked SMARCA4 in our
study (clear cell carcinoma) is not in the differential
diagnosis of SCCOHT. These data demonstrate that
the lack of SMARCA4 in ovarian tumours is a highly
sensitive and almost completely specific IHC marker of
SCCOHT.
Absence of SMARCA2 protein in SCCOHT tumours
In order to determine SMARCA2 status in SCCOHT
and the potential for its development as a therapeutic
target, we examined its expression in 45 cases. All
45 tumours (43 lacking SMARCA4 and 2 lacking
SMARCB1) were negative for SMARCA2. How-
ever, rare tumour cells (usually< 1% but up to 10%
focally) still expressed SMARCA2. In areas containing
only small cells, SMARCA2 staining was exclusively
nuclear (Figure 1A, arrows). In tumours with a large
cell component, the protein was exclusively localized to
the cytoplasm of large cells (Figure 1B, bottom panels,
arrowheads), with no cytoplasmic expression in the
small cell component (Figure 1B, upper panels).
We did not identify mutations in the SMARCA2 gene
in SCCOHT, implicating silencing during tumourigen-
esis or in the cell of origin as the underlying mecha-
nism explaining the absence of SMARCA2 protein. We
therefore performed IHC for SMARCA2 in ovaries of
premenopausal women and found uniform and strong
expression in all ovarian cell types, including surface
epithelial cells, stromal cells, granulosa cells, theca
cells, and oocytes (Figure 1C). This result suggests that
SCCOHT loses SMARCA2 expression during tumouri-
genesis or, alternatively, SCCOHT arises from a rare
SMARCA2-negative cell type in the ovary.
To determine whether dual loss of both SMARCA4
and SMARCA2 was specific for SCCOHT, we exam-
ined SMARCA2 expression by IHC in ovarian clear cell
carcinoma, the only other tumour lacking SMARCA4
expression (Table 1). Tumours were deficient either for
SMARCA4 or for SMARCA2, but not both (Figure 2),
indicating that dual deficiency of the two SWI/SNF
ATPases is specific for SCCOHT. In uterine tumours,
combined SMARCA4 and SMARCA2 deficiency was
only observed in dedifferentiated carcinoma (n= 1) and
high-grade ESS (n= 2) (Figure 3).
Epigenetic silencing of SMARCA2 in SCCOHT cells
The lack of mutations or deletions involving SMARCA2
in SCCOHT and the expression of SMARCA2 protein in
rare tumour cells suggest that the absence of SMARCA2
protein in most tumour cells arises from epigenetic
silencing or mRNA degradation, as reported in other
SMARCA2-deficient cell lines [17–21]. Comparedwith
normal premenopausal ovary, SMARCA2 mRNA levels
were decreased in seven SCCOHT tumour samples
(four primary tumours and two mouse xenografts gen-
erated directly from patient tumours, and one SCCOHT
cell line), an effect that was specific for SMARCA2 and
not observed with genes encoding most other SWI/SNF
family members (Figure 4A). Similar to the tumour
samples, no SMARCA2 mRNA (Figure 4B) or protein
(Figure 4C, S1) was detected in two SCCOHT cell lines,
BIN67 and SCCOHT1, and no underlying mutation was
identified. SMARCA2 mRNA levels were significantly
lower in BIN67 and SCCOHT1 cells than in NOY1 (a
yolk sac tumour cell line), SVOG3e (an immortalized
primary granulosa cell line) or KGN cells (an adult
granulosa cell tumour cell line) (Figure 4B), suggesting
epigenetically silencing of the SMARCA2 gene or degra-
dation of SMARCA2 mRNA as the mechanism underly-
ing the lack of SMARCA2 protein in SCCOHT cells.
To determine whether we could reactivate SMARCA2
expression in SCCOHT cell lines, we treated BIN67
cells with inhibitors that target epigenetic regulators
including the HDAC inhibitor trichostatin A (TSA),
the DNA methyltransferase inhibitor 5-azacytidine
(5-AZA), and the EZH2 histone methyltransferase
inhibitor GSK343. Of these reagents, only the HDAC
inhibitor TSA induced the expression of SMARCA2
protein (Figure 4D), correlating with increased mRNA
levels in BIN67 cells (Figure 4E). Furthermore, TSA
stimulated the expression of SMARCA2 protein in a
dose-dependent manner in BIN67 and SCCOHT1 cells
(Figure 4 F). These data implicate HDAC-mediated epi-
genetic silencing of the SMARCA2 gene in SCCOHT or,
alternatively, an indirect inhibitory effect on SMARCA2
mRNA degradation.
Re-expression of SMARCA4 or SMARCA2 inhibits
cell growth
To assess whether the absence of SMARCA4 and
SMARCA2 is crucial for tumour cell growth, we
infected BIN67 cells with lentiviruses driving expres-
sion of SMARCA4 or SMARCA2. Overexpression
of either protein robustly suppressed the growth
of BIN67 cells (Figure 5A). However, SMARCA4
expression did not significantly inhibit the growth of
cells lacking only SMARCA4 (JHOC5 cells, ovarian
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 389–400
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
394 AN Karnezis et al
Figure 1. Immunohistochemical analysis of core SWI/SNF proteins in SCCOHT. (A) Dual loss of SMARCA4/BRG1 and SMARCA2/BRM in
SCCOHT. Endothelium and lymphocytes are internal positive controls for both proteins. Arrows denote rare tumour cells expressing
SMARCA2. SMARCB1/INI1 protein expression serves as a positive control for tumour cell immunoreactivity. (B) SMARCA2/BRM expression
and subcellular localization in regions of small cell versus large cell morphology. When present, SMARCA2 only showed nuclear localization
in the small cells (arrows, A). In contrast, scattered tumour cells with large cell morphology also expressed SMARCA2 in the cytoplasm
(arrowheads, B). (C) SMARCA4/BRG1 and SMARCA2/BRM expression in normal ovary from premenopausal women. SMARCA4 was expressed
strongly in oocytes and granulosa cells but was either weak or absent in stromal cells. In contrast, SMARCA2 showed diffuse and strong
expression in oocytes, granulosa cells, and stromal cells. In addition, both proteins showed uniform expression in ovarian surface epithelium
(data not shown). H&E and SMARCA4 immunohistochemistry images are reproduced from our previous publication, Ramos et al [2]
(Supplementary Figure 4, panels A–D).
clear cell carcinoma cell line [22]) or with normal
SMARCA4 and SMARCA2 expression (ES-2 ovar-
ian endometrioid adenocarcinoma cell line [22])
(data not shown). Previous studies have shown that
the ability of SMARCA4 to induce cell cycle arrest
in SMARCA4/SMARCA2-deficient cell lines is
dependent on a functional retinoblastoma growth
control pathway [17,19,23–26]. Therefore, the rapid
growth arrest that SMARCA4 or SMARCA2 expression
induced in SCCOHT cells is consistent with the absence
of detectable RB1 gene mutations in all tumour samples
and the presence of intact, full length RB1 protein (both
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 389–400
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
SMARCA4/SMARCA2 loss in small cell carcinoma, hypercalcaemic type 395
Figure 2. Immunohistochemical analysis of SMARCA4/BRG1 and SMARCA2/BRM in ovarian clear cell carcinoma. Tumours were negative for
either SMARCA4 (middle panels) or SMARCA2 (bottom panels) or showed intact expression of both proteins (upper panels). No dual deficient
tumours were identified. Similar to SCCOHT, rare scattered SMARCA2-positive cells (arrows) were identified in some SMARCA2-negative
tumours.
hypo- and hyper-phosphorylated forms) in the BIN67
cells (data not shown).
Discussion
SMARCA4 in ovarian and endometrial tumours
Almost all SCCOHTs contain inactivating somatic and
germline mutations in SMARCA4 that result in loss
of the SMARCA4 (BRG1) protein. We investigated
SMARCA4 expression by IHC in a large collection
of gynaecological and non-gynaecological tumours
to determine the specificity of SMARCA4 loss for
SCCOHT. All tumours in the differential diagnosis
that we examined retained SMARCA4 expression.
The only primary ovarian tumour other than SCCOHT
that showed loss of SMARCA4 – clear cell carci-
noma – does not enter the histological differential
diagnosis of SCCOHT. Therefore, the absence of
SMARCA4 is highly sensitive and essentially com-
pletely specific for SCCOHT.
Though we only studied small numbers of germ cell
tumours in the differential diagnosis of SCCOHT, our
results are consistent with those of Witkowski et al,
who found no SMARCA4 mutations in 106 germ cell
tumours, including 25 dysgerminomas and seminomas
[27]. A few ovarian tumours in the differential diagno-
sis of SCCOHT were not studied, including metastatic
small cell lung carcinoma and oxyphilic tumours that
can resemble the large cell variant of SCCOHT. In
addition, we did not examine small cell carcinoma of
the endometrium or cervix; notably, the latter has been
reported to be deficient in SMARCA4 [28]. Though
SCCOHT and cervical small cell carcinoma have dis-
tinct clinical presentations, other IHC markers (eg WT1
and TTF1) [29] or molecular studies (HPV18 in the cer-
vical tumours) [28,30] can also be used to distinguish
between these entities.
The near universal expression of SMARCA4 as
determined by IHC contrasts with the presence of
SMARCA4 point mutations or deletions reported in
several tumours in our study such as high-grade serous
carcinomas [9,10,31–33]. Different mutation types
in these tumours compared with those in SCCOHT
likely underlie this apparent discrepancy. Of almost
100 SMARCA4 mutations reported in SCCOHT, all
but three are destructive to the protein (truncating,
frameshift, spice site or deletions) [15] with com-
mon bi-allelic inactivation due to mutation or loss of
heterozygosity of the second allele [3,5]. In contrast,
approximately 80% of SMARCA4 mutations found in
more than 500 other tumour samples are missense and
do not typically involve inactivation of the second allele
[9,10,31,32]. Therefore, several tumours in our study
may harbour missense mutations in SMARCA4 that, by
their nature, were not suggested by IHC. Interestingly,
although ovarian high-grade serous carcinomas report-
edly show mutually exclusive homozygous deletions in
SMARCA4 and SMARCA2 [31,32], we did not observe
SMARCA4 protein loss in any of our samples. This
apparent discrepancy might be explained by the extreme
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Figure 3. Immunohistochemical analysis of SMARCA4/BRG1 and SMARCA2/BRM in endometrial stromal sarcoma (ESS) and dedifferentiated
carcinoma (DDC) of the uterus. Three uterine tumour types showed SMARCA4/BRG1 deficiency: low-grade ESS (LGESS, n= 2, upper panels),
high-grade ESS (HGESS, n= 2, middle panels), and DDC (n= 1, lower panels). Both cases of SMARCA4-negative LGESSmaintained expression
of SMARCA2. In contrast, both HGESS and the DDC that lacked SMARCA4 were also deficient in SMARCA2.
intratumoural heterogeneity [34] that characterizes this
tumour. Accordingly, it seems unlikely that random
selection of two different areas of a tumour for inclu-
sion in a TMA would result in all tumour cells in both
regions having homozygous deletions in SMARCA4.
Silencing of SMARCA2 in SCCOHT
Several groups recently demonstrated that SMARCA4-
deficient lung cancer cells depend on SMARCA2,
the other mutually exclusive ATPase in SWI/SNF
complexes, for proliferation and survival [11,12,35],
suggesting that SMARCA2 could be a therapeu-
tic target in SMARCA4-mutant tumours. However,
this requirement is not absolute, as some cell lines
[11–13,17,19,23–26] and lung cancers [36,37] lack
both ATPases. Similar to the lung cancers with poor
prognosis that lack both SMARCA4 and SMARCA2
[37], all SMARCA4-deficient SCCOHTs were also
deficient for SMARCA2. In addition, as previously
reported for other SMARCA4-mutant tumours with loss
of SMARCA2 expression [18–21], we could restore
SMARCA2 expression by treatment of SCCOHT cell
lines with the HDAC inhibitor TSA. We have found that
HDAC inhibitors are potent inducers of SMARCA2 and
growth arrest in SCCOHT cell lines (data not shown).
Based on the pleotropic effects of HDAC inhibitors
on global gene expression, we think that it is unlikely
that SMARCA2 up-regulation is the sole mechanism
by which these agents cause growth arrest. We are
currently performing shRNA studies against SMARCA2
and with specific HDACs (guided by the known
HDAC specificity of the particular HDAC inhibitors)
to determine the role that SMARCA2 plays in HDAC
inhibitor-induced growth arrest and which HDACs
mediate the growth inhibitory effect. Therefore, our
results strongly support silencing, either transcriptional
or post-transcriptional, as the mechanism underlying the
absence of SMARCA2 gene expression in these tumours
and implicate HDAC inhibitors as potential treatment
options.
Among ovarian tumours, dual loss of SMARCA4 and
SMARCA2 was only observed in SCCOHT. Ovarian
clear cell carcinomas lacked SMARCA4 or SMARCA2
but not both. Similarly, Huang et al recently reported
no loss of SMARCA4 in 68 ovarian clear cell carcino-
mas, with only one tumour showing SMARCA2 loss
[38], and although almost all SCCOHT tumour cells
lacked SMARCA2, rare SMARCA2-positive tumour
cells were identified and the subcellular localization
correlated with cell morphology – exclusively nuclear
in small cells and either nuclear or cytoplasmic in
large cells. Cytoplasmic SMARCA2 in large cells of
SCCOHT is reminiscent of the cytoplasmic SMARCB1
staining observed in some cases of epithelioid sarcoma
[39]. These findings suggest that in addition to mutation
and gene silencing, SWI/SNF defects may also be due
to protein mislocalization.
Potential cells of origin
SCCOHT may arise from resident ovarian cells or
from a cell type within an immature teratoma [4]. The
conspicuous lack of SMARCA2 mutations in three
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Figure 4. SMARCA2 silencing in SCCOHT tumours and cell lines and reactivation by the histone deacetylase inhibitor trichostatin A.
(A) Heat map depicting the expression of genes encoding SWI/SNF family members in SCCOHT tumours (SCCO-002, -012, -014, and
-015), patient-derived mouse xenografts (PDX-040 and −065), and SCCOHT cell lines (BIN67 and SCCOHT1). SMARCA2 mRNA is strongly
down-regulated in contrast to almost all other SWI/SNF genes. Premenopausal ovaries were used as a reference. (B) Real-time PCR of
steady-state SMARCA4 and SMARCA2 mRNA levels in SCCOHT cell lines (BIN67 and SCCOHT1) compared with other ovarian cell lines.
SVOG3e: immortalized granulosa cells; KGN: adult granulosa cell line; NOY1: yolk sac tumour cell line. Levels of mRNA were normalized to
GAPDH. (C) Western blotting for SMARCA4 and SMARCA2 in SCCOHT cell lines. Vinculin served as a loading control. Both SCCOHT cell lines
expressed SMARCB1/INI1 (data not shown), similar to primary tumours (Figure 1A). (D) Specific up-regulation of SMARCA2/BRM protein by
the histone deacetylase inhibitor trichostatin A (TSA). BIN67 cells were treated for 72 h with TSA, GSK343, trametinib or 5-azacytidine, and
SMARCA2 expression was analysed by western blotting. Ctrl denotes vehicle treatment. SMARCA2 (lane 2) denotes cells transduced with
lentivirus expressing SMARCA2. KGN: adult granulosa cell tumour cells. Ponceau S staining served as a loading control. (E) Real-time PCR
of SMARCA4 and SMARCA2 mRNA levels in BIN67 cells after 72 h of treatment with 0.6 μM TSA. Although absolute baseline SMARCA2
mRNA levels are significantly lower than SMARCA4 (Figure 4B), both are arbitrarily set to 1 in this experiment. SMARCA2 mRNA levels are
strongly up-regulated by TSA compared with SMARCA4. (F) SMARCA2 protein up-regulation is TSA-dose-dependent in SCCOHT cell lines.
BIN67 and SCCOHT1 cells were treated with increasing doses of TSA for 72 h, and SMARCA2 expression was analysed by western blotting.
Ctrl denotes vehicle treatment. SMARCA2 (lane 2 for each cell line) denotes cells transduced with lentivirus expressing SMARCA2. ES-2:
ovarian endometrioid adenocarcinoma cells. Ponceau S staining served as a loading control.
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Figure 5. Re-expression of SMARCA4 or SMARCA2 suppresses
SCCOHT cell growth. (A) BIN67 cells were transduced with
lentiviruses expressing GFP, SMARCA4 or SMARCA2 and seeded at
a density of 4000 cells per well in 96-well plates for monitoring
cell growth using an IncuCyte ZOOM® live cell monitor. The per-
centage of confluence in each well was calculated and plotted to
determine the effect of SMARCA4 or SMARCA2 re-expression on
cell growth. (B) Re-expression of SMARCA4 or SMARCA2 was con-
firmed by western blotting. Ponceau S staining served as a loading
control.
papers that identified the SMARCA4 mutation in
SCCOHT by next-generation sequencing [2,3,5],
together with the up-regulation of SMARCA2 mRNA
and translated protein by the histone deacetylase
inhibitor trichostatin A, indicates that the lack of
SMARCA2 protein expression is due to either epi-
genetic or post-transcriptional silencing. The lack
of SMARCA2 expression in tumours may reflect
either its original absence in the cell of origin or
silencing as a pathogenic event during tumourige-
nesis. Lentivirus-mediated restoration of wild-type
SMARCA4 does not result in re-expression of
endogenous SMARCA2 protein, whereas HDAC
inhibitors do result in SMARCA2 protein expression
(data not shown). This differential SMARCA2 protein
up-regulation is not likely due to differences in the
effects of SMARCA4 expression or HDAC inhibitor
treatment on the cell cycle since both manipulations
result in growth arrest. We speculate that the inabil-
ity of exogenous SMARCA4 to restore endogenous
SMARCA2 expression reflects the origin of SCCOHT
from a rare SMARCA2-negative cell.
Molecular pathogenesis
The function of the SWI/SNF complex in transcriptional
regulation, the absence of other recurrent mutations, and
the diploid cytogenetic profile of SCCOHT indicate that
the principal mechanism of oncogenesis is epigenetic
dysregulation. The pathological features – poorly dif-
ferentiated and highly proliferative – suggest that the
principal defect is the failure to activate genes that pro-
mote or maintain terminal differentiation.
The role of the SWI/SNF complex in regulating differ-
entiation as a potential mechanism of SCCOHT patho-
genesis is also suggested by the uterine tumours with
combined loss of both SMARCA4 and SMARCA2 –
dedifferentiated carcinoma and high-grade ESS. These
tumours are conceptually similar in that they both
have low- and high-grade areas separated by an abrupt
transition indicating a dedifferentiation event and, like
SCCOHT, they both can show small cell or rhabdoid fea-
tures in the high-grade areas [16,40].
We propose that dual deficiency in core members of
the SWI/SNF complex (eg SMARCA4 and SMARCA2
or SMARCB1 and SMARCA2) induces dedifferenti-
ation from a normal cell or a low-grade tumour into
an aggressive high-grade tumour with small cell and/or
rhabdoid features. Similar to our findings in SCCOHT,
malignant rhabdoid tumours also show dual deficiency
for core SWI/SNF members: SMARCB1 by mutation
and SMARCA2 by non-mutational silencing [41–43].
The shared clinicopathological features of SCCOHT
and rhabdoid tumours of the brain and kidney – lethal
behaviour, diploid cytogenetics, small cell/rhabdoid his-
tology, and dual loss of core SWI/SNF components
(one by mutation, one by silencing) – support the pro-
posal that SCCOHT is a malignant rhabdoid tumour
of the ovary, as proposed by Foulkes et al [44]. More
importantly, the shared genetics of rhabdoid tumours
will hopefully predict their response to drugs that tar-
get epigenetic modifications. Our preliminary studies on
HDAC inhibitors support this notion.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Figure S1. Specificity of SMARCA4 and SMARCA2 antibodies by western blot.
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